

RealRate

PHARMACEUTICAL 2023

Atea Pharmaceuticals Inc. Rank 29 of 446









RealRate



Atea Pharmaceuticals Inc. Rank 29 of 446

The relative strengths and weaknesses of Atea Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Atea Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Atea Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 270%, being 227% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	660,922
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,478
Liabilities, Non-Current	2,403
Other Assets	4,081
Other Compr. Net Income	-684
Other Expenses	45,124
Other Liabilities	5,255
Other Net Income	0
Other Revenues	11,151
Property and Equipment	1,705
Research and Development	81,936
Selling, General and Administrative Expense	48,714

Output Variable	Value in 1000 USD
Assets	666,708
Liabilities	26,136
Expenses	175,774
Revenues	11,151
Stockholders Equity	640,572
Net Income	-164,623
Comprehensive Net Income	-164,965
Economic Capital Ratio	270%

